New combo attack: surgery and drugs take on tough liver cancer
NCT ID NCT04649489
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether liver surgery followed by two drugs (atezolizumab and bevacizumab) can help people with liver cancer that has spread into veins. The study includes 501 participants who have not had prior treatment. The goal is to see if this approach delays cancer progression and improves survival compared to drug treatment alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs)
What this could lead to
If successful, this could show that combining surgery with these drugs improves survival for people with advanced liver cancer and vein clots.
What could go wrong
This is an early-stage trial with no results yet. The combination may not work better than current treatments, and surgery carries risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, China
-
Beijing Cancer Hospital
Beijing, China
-
Cancer Hospital Chinese Academy of Medical Science
Beijing, China
-
Fujian Provincial Hospital
Fuzhou, China
-
Guangxi Medical University Cancer Hospital
Nanning, China
-
Henan Province People Hospital
Zhengzhou, China
-
Jiangsu Provine People Hospital
Nanjing, China
-
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, China
-
Peking Union Medical College Hospital
Beijing, China
-
Peking Univerty People's Hospital
Beijing, China
-
Shanghai Jiao Tong University Ruijin Hospital
Shanghai, China
-
Sun Yat-sen University Cancer Center
Guangzhou, China
-
The First Affiliated Hospital Of Guangxi Medical University
Nanning, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
-
The First Hospital of Lanzhou University
Lanzhou, China
-
The Second Affiliated Hospital Kunming Medical University
Kunming, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
-
Tongji Hospital of Tongji Medical College of HUST
Wuhan, China
-
West China Hospital of Sichuan University
Chengdu, China
-
Xiangya Hospital of Central South University
Changsha, China
-
Zhongshan hospital, Fudan University
Shanghai, Shanghai Municipality, 200000, China